Breast Cancer-Targets and Therapy

Papers
(The TQCC of Breast Cancer-Targets and Therapy is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Comparative Analysis of Women’s Breast Cancer Survival Time at Three Selected Government Referral Hospitals in Ethiopia’s Amhara Region Using Parametric Shared Frailty Models46
Genetic Alterations in HER2-Positive and Equivocal Breast Cancer by Immunohistochemistry42
Transcriptome Profiling Analysis of Breast Cancer Cell MCF-7 Treated by Sesamol34
Chromosomal Instability as Enabling Feature and Central Hallmark of Breast Cancer20
How Does Patient Socioeconomic Position Affect Breast Cancer Surgical Treatment and Mortality?: A Rapid Review20
Programmed Death-Ligand 1 Expression in Breast Cancer Patients: Clinicopathological Associations from a Single-Institution Study20
Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India20
Risk of Subsequent Breast Cancer in Women with Early Stage HER2-Positive Breast Cancer in a Large Community Health Plan13
Analysis of Mammography BI-RADS Distribution and Follow-up Ultrasound Assessment: A Single-Center Study12
Update on Pulmonary Toxicity Induced by New Breast Cancer Treatments11
Adipokines in Breast Cancer: Decoding Genetic and Proteomic Mechanisms Underlying Migration, Invasion, and Proliferation11
Validation of a Disease-Free Survival Prediction Model Using UBE2C and Clinical Indicators in Breast Cancer Patients10
Breast Self-Examination Practice and Associated Factors Among Women Attending Family Planning Service in Modjo Public Health Facilities Southwest Ethiopia [Letter]10
Role of AURKB Inhibition in Reducing Proliferation and Enhancing Effects of Radiotherapy in Triple-Negative Breast Cancer10
The Prognostic Value of Serum Albumin to Globulin Ratio in Patients with Breast Cancer: A Retrospective Study9
Development and Validation of an MRI Radiomics-Based Signature to Predict Histological Grade in Patients with Invasive Breast Cancer8
Disparities in Guideline-Concordant Initial Systemic Treatment in Women with HER2-Negative Metastatic Breast Cancer: A SEER-Medicare Analysis8
Shenqi Fuzheng Injection Reduces Cisplatin-Induced Kidney Injury via cGAS/STING Signaling Pathway in Breast Cancer Mice Model7
miR-623 Targets Metalloproteinase-1 and Attenuates Extravasation of Brain Metastatic Triple-Negative Breast Cancer Cells7
MCM-2 Levels as a Potential Biomarker for Predicting High-Risk Breast Cancer Patients According to TAILORx Classification7
The Role of Ki-67 in HR+/HER2- Breast Cancer: A Real-World Study of 956 Patients7
Hypofractionated versus Conventional Postmastectomy Irradiation for Breast Cancer: Comparison of Acute Skin Toxicity7
A Real-World Data Retrospective Cohort Study of Low Estrogen Receptor-Positive Early Breast Cancer: Natural History and Treatment Outcomes7
Predictive and Prognostic Value of TRIM58 Protein Expression in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy5
Young Women with Breast Cancer in Resource-Limited Settings: What We Know and What We Need to Do Better5
A Prospective Tumour Marker for Breast Cancer: YWHAB and Its Role in Promoting Oncogenic Phenotypes5
Breast Cancer Subtypes and Prognosis: Answers to Subgroup Classification Questions, Identifying the Worst Subgroup in Our Single-Center Series5
Based on BATMAN-TCM to Explore the Molecular Mechanism of Xihuang Pill Regulating Immune Function to Treat Breast Precancerous Lesions5
The Clinical Study of Intratumoral and Peritumoral Radiomics Based on DCE-MRI for HER-2 Positive and Low Expression Prediction in Breast Cancer5
Traditional Chinese Medicine for Breast Cancer: A Review5
Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab5
Cancer Treatment-Induced Bone Loss: Role of Denosumab in Non-Metastatic Breast Cancer5
Clinical Outcomes of Patients with HER2 Positive Metastatic Breast Cancer to the Brain, with First-Line Trastuzumab, Pertuzumab and Chemotherapy, in a Real-World Setting4
Real-World Analysis of the Efficacy and Adverse Events of T-DM1 in Chinese Patients With HER2-Positive Breast Cancer4
Research Progress on Molecular Subtyping and Modern Treatment of Triple-Negative Breast Cancer4
Role of Surgery in Metastatic Breast Cancer: Insights from a Narrative Review4
Recent Advances in Immunotherapy for Breast Cancer: A Review4
Identification and Validation of circDOCK1/miR-138-5p/GRB7 Axis for Promoting Breast Cancer Progression4
Dysregulation of Fatty Acid Metabolism in Breast Cancer and Its Targeted Therapy4
Amplifying Immune Responses: Microparticulate Vaccine Approach Against Breast Cancer4
Serum Direct Bilirubin as a Biomarker for Breast Cancer4
Diagnosis, Prognosis, and Treatment of Triple-Negative Breast Cancer: A Review4
Significance of Nuclear Factor-Kappa B (NF-κB) and Survivin in Breast Cancer and Their Association with Radiosensitivity and Prognosis4
Progranulin and Breast Cancer Mortality: 13-Year Follow-Up of a Cohort Study3
Central Nervous System Metastases from Triple-Negative Breast Cancer: Current Treatments and Future Prospective3
A Comprehensive Model Based on Dynamic Contrast-Enhanced Magnetic Resonance Imaging Can Better Predict the Preoperative Histological Grade of Breast Cancer Than a Radiomics Model3
Critical Evaluation of Secondary Cancer Risk After Breast Radiation Therapy with Hybrid Radiotherapy Techniques3
GNPNAT1 is a Biomarker That Predicts a Poor Prognosis of Breast Cancer3
Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer3
Jawbone Cavitation Expressed RANTES/CCL5: Case Studies Linking Silent Inflammation in the Jawbone with Epistemology of Breast Cancer3
The Involvement of Insulin-Like Growth Factor 2 Messenger Ribonucleic Acid-Binding Protein 2 in the Regulation of the Expression of Breast Cancer-Related Genes3
Early Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Breast Cancer Treated with Eribulin After Prior Immuno-Oncology or Antibody–Drug Conjugate Therapy3
Ultra-Hypofractionated Whole Breast Radiotherapy with Automated Hybrid-VMAT Technique: A Pilot Study on Safety, Skin Toxicity and Aesthetic Outcomes3
Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer3
A Novel Peroxisome-Related Gene Signature Predicts Breast Cancer Prognosis and Correlates with T Cell Suppression3
Invasive Breast Cancer with HER2 ≥4.0 and3
Rhabdomyolysis Induced by the Interaction Between Ribociclib and Statins- Case Report and Literature Review3
Predictive miRNAs Patterns in Blood of Breast Cancer Patients Demonstrating Resistance Towards Neoadjuvant Chemotherapy3
A Review on the Management of Peripheral Neuropathic Pain Following Breast Cancer3
On Ultrasonographic Features of Mucinous Carcinoma with Micropapillary Pattern3
Disabling the Nuclear Translocalization of RelA/NF-κB by a Small Molecule Inhibits Triple-Negative Breast Cancer Growth3
Insights into the Refusal of Free Screening Mammograms: Exploring Contributing Factors3
Feasibility Study of Pyrrolitinib-Based Dual-Target Therapy for Neoadjuvant Treatment of HER2-Positive Breast Cancer Patients3
Pyrotinib for Elderly Patients with Advanced HER2-Positive Breast Cancer3
The Effect of C-Reactive Protein/Lymphocyte Ratio (CLR) on PFS in Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors: A Novel Biomarker3
Serum HER2 Level Predicts Therapeutic Efficacy and Prognosis in Advanced Breast Cancer Patients [Letter]3
0.61245799064636